PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1665281
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1665281
The Global Sclerotherapy Market was valued at USD 1.3 billion in 2024 and is projected to grow at a robust compound annual growth rate (CAGR) of 6.1% from 2025 to 2034. This growth is primarily fueled by the increasing prevalence of vascular disorders, a rising preference for minimally invasive treatment options, regulatory approvals for advanced sclerosants, and the expanding use of sclerotherapy as a cost-effective alternative to surgery.
The market is segmented into chemical irritants, detergents, and osmotic agents. In 2024, the detergents segment led the market with a dominant share of 68.1%. Detergents are the preferred choice due to their high efficiency, protective profile, and flexibility compared to other types of sclerosing agents. Popular detergents, such as polidocanol and sodium tetradecyl sulfate, are widely used for both cosmetic and medical treatments of varicose and spider veins. These agents are known for their lower risk of complications, including allergic reactions and hyperpigmentation when compared to osmotic agents and chemical irritants.
Market Scope | |
---|---|
Start Year | 2024 |
Forecast Year | 2025-2034 |
Start Value | $1.3 Billion |
Forecast Value | $2.3 Billion |
CAGR | 6.1% |
The sclerotherapy market is also divided into foam sclerotherapy, liquid sclerotherapy, ultrasound sclerotherapy, and other therapies. In 2024, the liquid sclerotherapy segment accounted for 46.9% of the market share. Liquid sclerotherapy is favored for its versatility, cost-effectiveness, and suitability for treating smaller veins, such as spider veins. As a more affordable option compared to foam-based or advanced treatments, it is accessible to patients and clinics with budget constraints. Additionally, liquid sclerotherapy carries a lower risk of side effects, such as embolization, when used for smaller veins, making it a safer alternative. The procedure itself is straightforward and requires minimal preparation, further adding to its appeal compared to foam or other therapies.
In the United States, the sclerotherapy market was valued at USD 483 million in 2024. The high prevalence of vascular diseases across the country is a key factor driving revenue growth in the market. Additionally, the U.S. benefits from a well-established healthcare infrastructure, with specialized hospitals and clinics equipped to perform sclerotherapy. Access to advanced diagnostic tools, such as ultrasound, further enhances the precision and effectiveness of treatments, contributing to the market's strong performance.